1 The National Oncology Center-Aden, Faculty of Medicine and Health Sciences, University of Aden.
2 The National Oncology Center - Shabwah, Faculty of Medicine and Health Sciences, University of Shabwah.
World Journal of Advanced Research and Reviews, 2026, 29(02), 310-318
Article DOI: 10.30574/wjarr.2026.29.2.0303
Received on 28 December 2025; revised on 03 February 2026; accepted on 06 February 2026
The integration of molecular genetics into lymphoma diagnostics and management has revolutionized hematologic oncology. This comprehensive review synthesizes the latest advances in molecular diagnostic techniques, risk stratification, and targeted therapeutic approaches for B-cell and T-cell lymphomas, with reference to contemporary guidelines and emerging clinical research. The paradigm shifts from morphology-based to genetics-integrated diagnostics has significantly enhanced diagnostic accuracy, prognostic precision, and personalized treatment strategies. We detail the clinical utility of fluorescence in situ hybridization (FISH), next-generation sequencing (NGS), gene expression profiling (GEP), and emerging technologies, along with their implications for targeted therapy selection, resistance monitoring, and clinical trial design. Special emphasis is placed on actionable genetic alterations that guide therapeutic decisions in routine practice and investigational settings.
Lymphoma; Molecular Genetics; FISH; NGS; Targeted Therapy; Precision Medicine; WHO Classification; Prognostic Biomarkers; Treatment Resistance; Hematopathology
Get Your e Certificate of Publication using below link
Preview Article PDF
Gamal Abdul Hamid and Ali Bawahal. Advances in Molecular Diagnosis, Prognostication and Targeted Therapy in Lymphoma: A Comprehensive Updated Review. World Journal of Advanced Research and Reviews, 2026, 29(02), 310-318. Article DOI: https://doi.org/10.30574/wjarr.2026.29.2.0303.
Copyright © 2026 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0